Respiratory Syncytial Virus Infections
Conditions
Brief summary
This is the first-in-human, single-center, randomized, double-blinded, placebocontrolled, single-dose and multiple-dose escalation Phase Ia study
Detailed description
Single ascending dose (SAD), healthy participants will be randomized to receive a single inhalational dose of either XW001 or placebo in each of the planned SAD cohorts. Multiple ascending dose (MAD), healthy participants will be randomized to receive inhalational doses of XW001 or placebo in each of the planned MAD cohorts.
Interventions
DRUGXW001
Inhaled XW001
DRUGPlacebo
Matched inhaled placebo
Sponsors
Hangzhou Sciwind Biosciences Co., Ltd.
Study design
Allocation
RANDOMIZED
Intervention model
SEQUENTIAL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)
Eligibility
Sex/Gender
ALL
Age
18 Years to 45 Years
Healthy volunteers
Yes
Inclusion criteria
1. Healthy subjects aged 18-45 years (including both ends), male or female; 2. Body mass index (BMI) of 19.0-28.0 kg/m2 (including both ends); 3. Subjects who fully understand the trial objectives, have a basic understanding of the pharmacological effects and possible risks of the investigational drug, and voluntarily sign an informed consent form; 4. Subjects who can communicate well with the investigators, and understand and abide by the requirements of this study.
Exclusion criteria
1. (Screening period) Subjects participated in any drug clinical trial or used the investigational drug within 3 months prior to the trial; 2. (Screening period/admission) Subjects with a medical history of diseases in cardiovascular system, digestive system, endocrine system, urinary system, nervous system, hematological, immunological (including personal or family history of hereditary immunodeficiency), or metabolic abnormalities, etc., that are still considered as clinically significantly by the investigators. 3. (Screening period) Subjects with previously diagnosed chronic obstructive pulmonary disease (COPD), asthma, or other clinically significant lung diseases, or with a medical history of acute upper and lower respiratory infection requiring intravenous injection of antimicrobial drugs or other hospitalization treatment within the past 3 months; 4. (Screening period/admission) Subjects who had underwent a surgery that is considered affecting the pharmacokinetics(PK) behaviors of the drug by the investigator within 6 months prior to the trial; 5. Patients with positive endogenous interleukin 29 (IL-29) level (i.e., the test result in the screening period is higher than the lower limit of quantification); 6. Subjects with lung function abnormality (measured forced expiratory volume in one second #FEV1)/predicted FEV1 ≤ 80% or measured forced vital capacity (FVC)/predicted FVC ≤ 80%); 7. Subjects who are unable to complete the study for other reasons or are not suitable to participate in the trial as judged by the investigators.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Safety/tolerance endpoints | 28 Days for Cohort A and 42 Days for Cohort B | Number and percentage of treatment emergent adverse events (TEAE) and serious adverse events (SAE) |
Countries
China
Outcome results
None listed